Skip to content
Disclosery

Tetragon Partners GP Ltd

Follow

13F filer, CIK 1515070, GRAND CAYMAN, Cayman Islands

Tetragon Partners GP Ltd reported $635,063,221 across 39 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-13. Its ten largest share positions make up 76.5% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-26-005024

Period
2026-06-30
Reported value
$635M
Holdings
39
Top 10 weight
76.5%
New
10
Sold out
7

Part of the filer group Tetragon Partners GP Ltd

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PATHadded+5,742,372$62.4M
ALKTnew+600,284$10.9M
RLAYadded+388,768$7.27M
CELCnew+64,110$6.71M
IONSadded+55,409$4.39M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
WBDreduced-673,725-$18M
PRAXexited-15,952-$5.14M
SLNOexited-102,125-$3.42M
AXSMexited-20,059-$3.39M
MPLTexited-112,115-$2.28M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0000919574-26-005024, largest first. % of portfolio is the value over $614,316,975, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PATHUIPATH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,950,000 shares; 2024Q4: 6,950,000 shares; 2025Q1: 8,950,000 shares; 2025Q2: 13,722,244 shares; 2025Q3: 16,950,000 shares; 2025Q4: 17,450,000 shares; 2026Q1: 25,207,628 shares; 2026Q2: 30,950,000 shares 30,950,000$336M54.76%+5,742,372Timeline
KGEIKOLIBRI GLOBAL ENERGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 7,070,568 shares; 2024Q4: 7,070,568 shares; 2025Q1: 7,070,568 shares; 2025Q2: 7,068,857 shares; 2025Q3: 7,070,568 shares; 2025Q4: 6,934,504 shares; 2026Q1: 6,834,504 shares; 2026Q2: 6,834,504 shares 6,834,504$33.8M5.51%0Timeline
AUTLAUTOLUS THERAPEUTICS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,000,000 shares; 2024Q4: 8,250,000 shares; 2025Q1: 8,600,000 shares; 2025Q2: 9,500,000 shares; 2025Q3: 9,500,000 shares; 2025Q4: 9,500,000 shares; 2026Q1: 9,500,000 shares; 2026Q2: 9,500,000 shares 9,500,000$15.2M2.47%0Timeline
LYFTLYFT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,000,000 shares; 2024Q4: 1,000,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,000,000 shares 1,000,000$14.6M2.38%0Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 199,994 shares; 2026Q2: 286,990 shares 286,990$13.5M2.2%+86,996Timeline
WKWORKIVA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 150,000 shares; 2025Q3: 150,000 shares; 2025Q4: 150,000 shares; 2026Q1: 250,000 shares; 2026Q2: 250,000 shares 250,000$12.1M1.97%0Timeline
CXMSPRINKLR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,200,000 shares; 2024Q4: 2,200,000 shares; 2025Q1: 2,200,000 shares; 2025Q2: 2,200,000 shares; 2025Q3: 2,200,000 shares; 2025Q4: 2,200,000 shares; 2026Q1: 2,200,000 shares; 2026Q2: 2,200,000 shares 2,200,000$11.4M1.85%0Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 177,840 shares; 2025Q4: 143,327 shares; 2026Q1: 145,480 shares; 2026Q2: 203,543 shares 203,543$11.2M1.83%+58,063Timeline
ALKTALKAMI TECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 600,284 shares 600,284$10.9M1.77%newTimeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 192,000 shares; 2025Q1: 261,000 shares; 2025Q2: 316,150 shares; 2025Q3: 303,600 shares; 2025Q4: 243,800 shares; 2026Q1: 312,316 shares; 2026Q2: 290,441 shares 290,441$10.8M1.76%-21,875Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 619,000 shares; 2025Q2: 699,000 shares; 2025Q3: 223,123 shares; 2025Q4: not reported; 2026Q1: 181,543 shares; 2026Q2: 570,311 shares 570,311$10.7M1.74%+388,768Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 81,841 shares; 2025Q4: 96,935 shares; 2026Q1: 127,198 shares; 2026Q2: 130,484 shares 130,484$10.6M1.73%+3,286Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 126,995 shares; 2025Q2: 188,100 shares; 2025Q3: 194,612 shares; 2025Q4: 194,612 shares; 2026Q1: 221,611 shares; 2026Q2: 295,627 shares 295,627$10.2M1.66%+74,016Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 15,632 shares; 2025Q3: 89,612 shares; 2025Q4: 141,172 shares; 2026Q1: 159,791 shares; 2026Q2: 189,979 shares 189,979$9.95M1.62%+30,188Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 131,167 shares; 2025Q2: 147,817 shares; 2025Q3: 188,379 shares; 2025Q4: 166,187 shares; 2026Q1: 218,507 shares; 2026Q2: 255,934 shares 255,934$9.86M1.61%+37,427Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 365,369 shares; 2026Q1: 630,161 shares; 2026Q2: 764,256 shares 764,256$8.39M1.37%+134,095Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 138,375 shares; 2025Q3: 223,181 shares; 2025Q4: 247,997 shares; 2026Q1: 258,132 shares; 2026Q2: 356,657 shares 356,657$7.92M1.29%+98,525Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 41,764 shares; 2026Q2: 97,173 shares 97,173$7.7M1.25%+55,409Timeline
AGIOAGIOS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 162,018 shares; 2026Q1: 164,839 shares; 2026Q2: 205,579 shares 205,579$7.63M1.24%+40,740Timeline
HRMYHARMONY BIOSCIENCES HLDGS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 82,824 shares; 2026Q1: 119,340 shares; 2026Q2: 201,036 shares 201,036$7.32M1.19%+81,696Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,870 shares; 2025Q4: 11,814 shares; 2026Q1: 19,668 shares; 2026Q2: 19,668 shares 19,668$7.31M1.19%0Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 784,355 shares; 2024Q4: 1,400,000 shares; 2025Q1: 2,650,000 shares; 2025Q2: 2,810,000 shares; 2025Q3: 2,112,455 shares; 2025Q4: 2,032,455 shares; 2026Q1: 1,292,455 shares; 2026Q2: 1,242,455 shares 1,242,455$7.09M1.15%-50,000Timeline
CELCCELCUITY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 64,110 shares 64,110$6.71M1.09%newTimeline
WBDWARNER BROS DISCOVERY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 923,725 shares; 2026Q2: 250,000 shares 250,000$6.67M1.08%-673,725Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 69,287 shares; 2026Q1: 103,037 shares; 2026Q2: 86,996 shares 86,996$6.07M0.99%-16,041Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 218,750 shares; 2025Q3: 258,242 shares; 2025Q4: 272,828 shares; 2026Q1: 317,877 shares; 2026Q2: 297,926 shares 297,926$5.35M0.87%-19,951Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 107,000 shares; 2025Q2: 161,396 shares; 2025Q3: 86,071 shares; 2025Q4: not reported; 2026Q1: 144,620 shares; 2026Q2: 167,875 shares 167,875$4.25M0.69%+23,255Timeline
CUECUE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 93,819 shares 93,819$2.96M0.48%newTimeline
SNOWSNOWFLAKE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,000 shares; 2024Q4: 10,000 shares; 2025Q1: 10,000 shares; 2025Q2: 10,000 shares; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 10,000 shares; 2026Q2: 10,000 shares 10,000$2.54M0.41%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 400,000 shares 400,000$2.12M0.34%newTimeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 187,500 shares; 2025Q2: 228,832 shares; 2025Q3: 243,728 shares; 2025Q4: not reported; 2026Q1: 37,588 shares; 2026Q2: 46,516 shares 46,516$1.6M0.26%+8,928Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 56,052 shares 56,052$1.36M0.22%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
AXSMAXSOME THERAPEUTICS INC. Stockcall35,000$8.57M0
RAREULTRAGENYX PHARMACEUTICAL IN COMcall100,000$3.34Mnew
SLNSILENCE THERAPEUTICS PLC ADScall300,000$3.29Mnew
KPTIKARYOPHARM THERAPEUTICS INC COMMON STOCKcall250,300$2.45M+200,300
AGIOAGIOS PHARMACEUTICALS INC COMcall50,000$1.86Mnew
TENXTENAX THERAPEUTICS INC COM NEWcall75,100$1.09Mnew
AMLXAMYLYX PHARMACEUTICALS INC COMcall8,500$153Knew

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PRAXPRAXIS PRECISION MEDICINES I15,952$5.14Mshares
SLNOSOLENO THERAPEUTICS INC102,125$3.42Mshares
AXSMAXSOME THERAPEUTICS INC.20,059$3.39Mshares
MPLTMAPLIGHT THERAPEUTICS INC112,115$2.28Mshares
AARDAARDVARK THERAPEUTICS INC316,621$1.19Mshares
RAREULTRAGENYX PHARMACEUTICAL IN39,473$827Kshares
KPTIKARYOPHARM THERAPEUTICS INC52,984$295Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-26-005024 base2026-08-13acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0000919574-26-005024 Quarter ended 2026-06-302026-08-13acceptance time not in the bulk data set
13F-HR 0000919574-26-003297 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0000902664-26-001035 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0000902664-25-005067 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0000902664-25-003596 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000902664-25-002362 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR/A 0000902664-25-001158 Quarter ended 2024-12-312025-02-21acceptance time not in the bulk data set
13F-HR 0000902664-25-000991 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0000902664-24-006552 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0000902664-24-005113 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0000902664-24-003608 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0000902664-24-001744 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0000902664-23-005531 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0000902664-23-004430 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0000902664-23-003045 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0000902664-23-001747 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0000902664-22-004855 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0000902664-22-003948 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0000902664-22-002973 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0000902664-22-001699 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0000902664-21-004952 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0000902664-21-003867 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0000902664-21-002781 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0000902664-21-001316 Quarter ended 2020-12-312021-02-12acceptance time not in the bulk data set
13F-HR 0000902664-20-003942 Quarter ended 2020-09-302020-11-13acceptance time not in the bulk data set
13F-HR 0000902664-20-003024 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0000902664-20-002117 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0000902664-20-000934 Quarter ended 2019-12-312020-02-12acceptance time not in the bulk data set
13F-HR 0000902664-19-004310 Quarter ended 2019-09-302019-11-14acceptance time not in the bulk data set
13F-HR 0000902664-19-003359 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0000902664-19-002323 Quarter ended 2019-03-312019-05-15acceptance time not in the bulk data set
13F-HR 0000902664-19-001036 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set
13F-HR 0000902664-18-004089 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0000902664-18-003135 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR/A 0000902664-18-003165 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR/A 0000902664-18-002255 Quarter ended 2017-12-312018-05-15acceptance time not in the bulk data set
13F-HR 0000902664-18-002257 Quarter ended 2018-03-312018-05-15acceptance time not in the bulk data set
13F-HR/A 0000902664-18-002264 Quarter ended 2017-09-302018-05-15acceptance time not in the bulk data set
13F-HR 0000902664-18-001051 Quarter ended 2017-12-312018-02-14acceptance time not in the bulk data set
13F-HR 0000902664-17-004310 Quarter ended 2017-09-302017-11-14acceptance time not in the bulk data set
13F-HR 0000902664-17-003281 Quarter ended 2017-06-302017-08-14acceptance time not in the bulk data set
13F-HR 0000902664-17-002348 Quarter ended 2017-03-312017-05-15acceptance time not in the bulk data set
13F-HR 0000902664-17-001064 Quarter ended 2016-12-312017-02-13acceptance time not in the bulk data set
13F-HR 0000902664-16-008783 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0000902664-16-007888 Quarter ended 2016-06-302016-08-15acceptance time not in the bulk data set
13F-HR 0000902664-16-007026 Quarter ended 2016-03-312016-05-13acceptance time not in the bulk data set
13F-HR/A 0000902664-16-006019 Quarter ended 2015-12-312016-02-19acceptance time not in the bulk data set
13F-HR 0000902664-16-005623 Quarter ended 2015-12-312016-02-12acceptance time not in the bulk data set
13F-HR 0000902664-15-004218 Quarter ended 2015-09-302015-11-13acceptance time not in the bulk data set
13F-HR 0001104659-15-059570 Quarter ended 2015-06-302015-08-13acceptance time not in the bulk data set
13F-HR 0001104659-15-038180 Quarter ended 2015-03-312015-05-14acceptance time not in the bulk data set
13F-HR 0001104659-15-010430 Quarter ended 2014-12-312015-02-13acceptance time not in the bulk data set
13F-HR/A 0001104659-15-009584 Quarter ended 2014-09-302015-02-12acceptance time not in the bulk data set
13F-HR 0001104659-14-080452 Quarter ended 2014-09-302014-11-13acceptance time not in the bulk data set
13F-HR 0001104659-14-060412 Quarter ended 2014-06-302014-08-13acceptance time not in the bulk data set
13F-HR 0001104659-14-038579 Quarter ended 2014-03-312014-05-14acceptance time not in the bulk data set
13F-HR 0001104659-14-010472 Quarter ended 2013-12-312014-02-14acceptance time not in the bulk data set
13F-HR 0001104659-13-084575 Quarter ended 2013-09-302013-11-14acceptance time not in the bulk data set
13F-HR 0001104659-13-062235 Quarter ended 2013-06-302013-08-09acceptance time not in the bulk data set